Search results for "pemphigus vulgaris"

showing 10 items of 16 documents

Mycophenolate is effective in the treatment of pemphigus vulgaris.

1999

Background Pemphigus vulgaris is a potentially life-threatening autoimmune disease. Although combination therapies with prednisone and azathioprine are usually effective in controlling the disease, some patients either do not respond to this treatment or show early relapses. Objective To find out whether mycophenolate mofetil would be an effective drug in controlling pemphigus vulgaris in patients who failed initial treatment with azathioprine and prednisone. Results Twelve patients who were initially diagnosed as having pemphigus vulgaris and had relapsed while undergoing treatment with azathioprine (1.5-2 mg/kg of body weight) and prednisolone (2 mg/kg of body weight) subsequently receive…

AdultMalemedicine.medical_specialtyCombination therapymedicine.medical_treatmentPrednisoloneAzathioprineDermatologyMycophenolic acidPrednisoneAzathioprineMedicineHumansChemotherapybusiness.industryPemphigus vulgarisGeneral MedicineMiddle AgedMycophenolic Acidmedicine.diseaseDermatologyPemphigusTreatment OutcomeChemotherapy AdjuvantPrednisoloneDrug Therapy CombinationFemalebusinessImmunosuppressive AgentsPemphigusmedicine.drugArchives of dermatology
researchProduct

Rituximab in refractory pemphigus vulgaris

2008

Pemphigus vulgaris (PV) is a severe chronic autoimmune blistering disease of skin and mucous membranes. The use of systemic corticosteroids in pemphigus has dramatically reduced its mortality rate, but the long-term use of steroids leads to severe side effects, many of which are serious. For this reason it is often necessary to add immunosuppressive agents to the regimen. However, there are occasional refractory cases in which therapy with conventionally accepted modalities is either not efficacious or not possible on account of side effects. Rituximab is a therapeutic monoclonal antibody targeting CD20, an integral membrane protein highly expressed on the surface of pre-B lymphocytes and a…

Adultmedicine.medical_specialtyAntigens CD19B-Lymphocyte SubsetsDrug ResistanceDermatologyDrug Administration ScheduleAntibodies Monoclonal Murine-DerivedPharmacotherapyRefractoryRituximab pemphigus vulgarisimmune system diseasesHumansImmunologic FactorsMedicineInfusions IntravenousCD20integumentary systembiologybusiness.industryRemission InductionPemphigus vulgarisAntibodies MonoclonalGeneral MedicineAntigens CD20medicine.diseaseDermatologyRegimenPemphigusMonoclonalImmunologybiology.proteinPrednisoneDrug Therapy CombinationFemaleRituximabRituximabbusinessImmunosuppressive AgentsPemphigusmedicine.drugDermatologic Therapy
researchProduct

Effects of metformin on autoimmune immunoglobins and interferon-γ in patients with early diagnosed pemphigus vulgaris: a prospective clinical trial.

2021

The management of pemphigus vulgaris (PV) is challenging. This study aimed to evaluate the immunomodulating effects of metformin on PV. The study was conducted in two phases: in the first phase, patients received routine first-line treatment (prednisolone plus azathioprine) for 2 months, then in the second phase, metformin was added to this regimen for another 2 months. After addition of metformin to the first-line medications, significant reductions were seen in serum IgG1 (reduced from 534.92 ± 134.83 mg/dL to 481.58 ± 130.46 mg/dL, P < 0.001), IgG4 (51.83 ± 27.26 mg/dL to 44.50 ± 26.05 mg/dL, P < 0.001) and interferon-γ (277.99 ± 108.71 pg/mL to 45.05 ± 17.080 pg/mL, P = 0.03) concentrat…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentAzathioprineDermatologyGastroenterologySubclassSteroidInterferon-gammaInternal medicinemedicineHumansProspective Studiesbusiness.industryPemphigus vulgarisMiddle Agedmedicine.diseaseMetforminMetforminClinical trialRegimenImmunoglobulin GPrednisoloneFemalebusinessPemphigusmedicine.drugClinical and experimental dermatologyReferences
researchProduct

Cyclophosphamide plus vincristine and prednisone in the treatment of severe pemphigus vulgaris refractory to conventional therapy

1992

Five patients with severe pemphigus vulgaris refractory to conventional therapy with azathioprine and corticosteroids were treated with cyclophosphamide, vincristine and prednisone. One patient was not evaluable, while the remaining four patients showed a complete response. Duration of response was in the range of 13-94 months. Toxicity was mainly represented by alopecia, myelosuppression and gastrointestinal side-effects such as nausea/vomiting. Although cyclophosphamide and vincristine may induce severe side-effects, this association may be useful in controlling severe disease resistant to previous conventional therapies.

0301 basic medicineMalemedicine.medical_specialtyVincristineCyclophosphamideAdolescentNausea030106 microbiologyAzathioprinemacromolecular substancesGastroenterology03 medical and health sciences0302 clinical medicineRefractoryPrednisoneInternal medicinemedicineHumansPharmacology (medical)CyclophosphamideAgedPharmacologybusiness.industryPemphigus vulgarisMiddle Agedmedicine.diseaseInfectious DiseasesOncologyVincristine030220 oncology & carcinogenesisVomitingPrednisoneDrug Therapy CombinationFemalemedicine.symptombusinessPemphigusmedicine.drug
researchProduct

Diagnostic Concordance between Optical Coherence Tomography and Histological Investigations for Immune-Mediated Desquamative Gingivitis: Observationa…

2021

Desquamative gingivitis (DG) denotes a heterogeneous immune-mediated disease for which early diagnosis represents a great challenge. The main aim of this study is to validate diagnostic concordance between specific Optical Coherence Tomography (OTC) patterns for DG related to oral Lichen Planus (OLP), Pemphigus Vulgaris (PV), and Mucous Membrane Pemphigoid (MMP) and definitive histological diagnosis. Forty-three patients with suspected immune-mediated DGs, were progressively recruited. Before biopsy, an OCT preliminary evaluation was performed using specific pre-determined OCT diagnostic patterns (i.e., morphology and localization of blisters, status of the basal membrane, epithelial thickn…

Pathologymedicine.medical_specialtyoptical coherencediagnosisHealth Toxicology and MutagenesisConcordancePemphigoid Benign Mucous Membraneimmune-mediated diseasestomographyArticlesymbols.namesakeOptical coherence tomographyBiopsymedicineHumansMedical diagnosisskin and connective tissue diseasesFisher's exact testmedicine.diagnostic_testintegumentary systembusiness.industryPemphigus vulgarisPublic Health Environmental and Occupational HealthRReproducibility of Resultsmedicine.diseaseGingivitiseye diseasesdesquamative gingivitisDesquamative gingivitisstomatognathic diseasessymbolsMedicineOral lichen planusbusinessTomography Optical CoherencePemphigusInternational Journal of Environmental Research and Public Health
researchProduct

Factitial pemphigus-like lesions

2007

The maxillofacial region is rarely subjected to self-inflicted conditions such as factitious disease. Nasal ulceration, facial emphysema, periorbital ecchymosis, mandibular subluxation, gingival and mucosal ulceration, dental and salivary gland pain and glossopharyngeal neuralgia have been reported as possible manifestations of factitious disease. We report a case of a young woman who presented with unilateral bullous and ulcerative oral and erythematous facial lesions that were initially diagnosed as pemphigus vulgaris but was later determined to be secondary to self-inflicted injuries. To the best of the authors? knowledge, this clinical scenario has not been previously reported in the co…

oralstomatognathic diseasespemphigus vulgarisUNESCO::CIENCIAS MÉDICASBullous:CIENCIAS MÉDICAS [UNESCO]erythematousfacialfactitious disease
researchProduct

Enteric-coated mycophenolate sodium in the treatment of refractory pemphigus

2010

Background  One of the major goals of pemphigus therapy is to reduce the patient’s cumulative exposure to systemic corticosteroids. To investigate the efficacy of enteric-coated mycophenolate sodium (EC-MPS), 10 patients with active, refractory pemphigus vulgaris (PV) or foliaceous (PF) were treated with EC-MPS (1440 mg daily) and prednisone (75 mg daily) over 18 months. Observations  Following EC-MPS/prednisone therapy, disease progression was inhibited between days 30 and 45 in 9/10 patients (8 PV; 1 PF). At 18 months, 8/9 PV patients had clinically quiescent disease; EC-MPS therapy was no longer required in two patients as a result of disease remission. The remaining PV patient showed no…

medicine.medical_specialtybusiness.industryPemphigus vulgarisMycophenolate SodiumAzathioprineDermatologymedicine.diseaseGastroenterologySurgeryPemphigusRefractoryPrednisoneInternal medicinemedicineAdjuvant therapyAdverse effectbusinessmedicine.drugInternational Journal of Dermatology
researchProduct

Treatment of pemphigus vulgaris with mycophenolate mofetil

1997

different pattern of diffusion changes in a 51-year-old woman with chronic epilepsy and recurrent episodes of focal status epilepticus, for whom no aetiology could be established. Status consisted of clonic jerking of the right leg, which continued for 22 days and was followed by transient paresis. DWI during status showed decreased diffusion in the motor cortex of the right leg (relative decrease in ADC of 27%, see figure). Surprisingly, the diffusion was increased in the subcortical white matter (relative increase in ADC of 31%). On the T2-weighted image (not shown), both cortex and subcortical white matter of the corresponding region returned a high signal similar to previously reported …

Pathologymedicine.medical_specialtyPrednisoloneAnti-Inflammatory AgentsMycophenolateMycophenolic acidWhite matterIMP DehydrogenaseCortex (anatomy)medicineHumansPremovement neuronal activityParesisbusiness.industryRemission InductionPemphigus vulgarisGeneral MedicineMycophenolic Acidmedicine.diseasemedicine.anatomical_structureDrug Therapy Combinationmedicine.symptombusinessImmunosuppressive AgentsPemphigusmedicine.drugMotor cortexThe Lancet
researchProduct

Epidemiology of desquamative gingivitis: evaluation of 125 patients and review of the literature

2009

Background  Desquamative gingivitis (DG) is a descriptive term used to indicate epithelial desquamation, erythema, erosions, and/or vesiculobullous lesions of the gingiva. DG is commonly associated with several mucocutaneous disorders and systemic conditions that may carry a poor prognosis and high morbidity; however, there are no clear data concerning the frequency of these disease associations. Methods  We investigated the epidemiologic features of DG in 125 patients and compared our findings with information from a literature review. Results  In our series, 88% of patients with DG had one of the following three disorders: oral lichen planus (OLP), mucous membrane pemphigoid (MMP), or pem…

AdultMalePathologymedicine.medical_specialtyErythemaAdolescentMucocutaneous zoneDermatologyGingivitisYoung AdultSettore MED/28 - Malattie OdontostomatologicheEpidemiologymedicineHumansSex organepidemiology desquamative gingivitisAgedAged 80 and overbusiness.industryPemphigus vulgarisMiddle Agedmedicine.diseaseDermatologyGingivitisDesquamative gingivitisstomatognathic diseasesOral lichen planusFemalemedicine.symptombusiness
researchProduct

Cleavage of desmoglein 3 can explain its depletion from keratinocytes in pemphigus vulgaris.

2008

We have previously demonstrated that serum of patients with pemphigus vulgaris induces reduction of desmoglein 3 (Dsg3) half-life in keratinocytes (FEBS Lett 2006: 580: 3276). This phenomenon seems to occur as a consequence of the progressive depletion of Dsg3 from desmosomes. Here we reported that reduction of full-length Dsg3 may be due to its progressive cleavage, leading to the formation of two fragmentation products with apparent molecular masses of about 60 kDa (fragment 1) and 70 kDa (fragment 2), as revealed by Western blotting. Unexpectedly, analysis of fragmentation pattern suggested cleavage to occur intracellularly. Consistently, fragment 1 was shed and localized within the cyto…

KeratinocytesPathologymedicine.medical_specialtyBlotting WesternPlakoglobinDermatologyBiologyCleavage (embryo)BiochemistryCell LinemedicineHumanseducationMolecular Biologyeducation.field_of_studyDesmoglein 3Desmoglein 1Pemphigus vulgarisBlood Proteinsmedicine.diseaseMolecular biologyBlotPemphigusmedicine.anatomical_structureDesmoplakinsDesmoglein 1Desmoglein 3gamma CateninKeratinocytePemphigusExperimental dermatology
researchProduct